<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Zentalis Pharmaceuticals Llc — News on 6ix</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc</link>
<description>Latest news and press releases for Zentalis Pharmaceuticals Llc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/zentalis-pharmaceuticals-llc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835dd9c78dffbe2df124cd3.webp</url>
<title>Zentalis Pharmaceuticals Llc</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc</link>
</image>
<item>
<title>Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-announces-abstract-acceptance-at-asco-2026-featuring-azenosertib-in-combination-with-paclitaxel-for-platinum-resistant-ovarian-cancer-4</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-announces-abstract-acceptance-at-asco-2026-featuring-azenosertib-in-combination-with-paclitaxel-for-platinum-resistant-ovarian-cancer-4</guid>
<pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
<description>Results from Part 1 of the Phase 1b MUIR trial to be presented at annual meeting in June SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Zentalis®</description>
</item>
<item>
<title>Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-to-present-azenosertib-preclinical-data-in-triple-negative-breast-cancer-and-real-world-analysis-of-unmet-need-in-cyclin-e1-positive-ovarian-cancer-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-to-present-azenosertib-preclinical-data-in-triple-negative-breast-cancer-and-real-world-analysis-of-unmet-need-in-cyclin-e1-positive-ovarian-cancer-at-aacr-2026</guid>
<pubDate>Fri, 17 Apr 2026 19:15:00 GMT</pubDate>
<description>Preclinical data show encouraging activity of azenosertib combinations in ADC-resistant TNBC, supporting the potential for pipeline expansion beyond ovarian cancer Real-world data demonstrate Cyclin E1-positive ovarian cancer patients have significantly worse outcomes, independent of CCNE1 gene amplification status, reinforcing the potential for azenosertib to address the unmet need for these patients SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a</description>
</item>
<item>
<title>Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-announces-400mg-qd-52-azenosertib-monotherapy-as-the-pivotal-study-dose-in-cyclin-e1-positive-platinum-resistant-ovarian-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-announces-400mg-qd-52-azenosertib-monotherapy-as-the-pivotal-study-dose-in-cyclin-e1-positive-platinum-resistant-ovarian-cancer</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles</description>
</item>
<item>
<title>Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-reports-full-year-2025-financial-results-and-operational-updates</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-reports-full-year-2025-financial-results-and-operational-updates</guid>
<pubDate>Thu, 26 Mar 2026 20:05:00 GMT</pubDate>
<description>On track for DENALI Part 2a dose confirmation in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalOn track to initiate the ASPENOVA Phase 3, randomized, confirmatory trial in 1H 2026Expanding azenosertib potential in ovarian cancer with the ongoing MUIR Part 2 trial evaluating the combination of azenosertib and bevacizumab as maintenance therapy$245.9 million cash, cash equivalents and marketable securities balance as of December 31,</description>
</item>
<item>
<title>Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-to-present-two-posters-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-to-present-two-posters-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026</guid>
<pubDate>Tue, 17 Mar 2026 20:30:00 GMT</pubDate>
<description>Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer Demonstration of Cyclin E1 protein overexpression as an indicator for poor prognosis in ovarian cancer patients with real world data SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a bioma</description>
</item>
<item>
<title>Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-participate-upcoming-investor-210500879</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-participate-upcoming-investor-210500879</guid>
<pubDate>Tue, 03 Feb 2026 21:05:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in a fireside discussion during Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11th in New York, NY at 3:30 p.m. ET. Access to a live web</description>
</item>
<item>
<title>Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-provides-corporate-highlights-130000383</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-provides-corporate-highlights-130000383</guid>
<pubDate>Tue, 06 Jan 2026 13:00:00 GMT</pubDate>
<description>Completed enrollment in DENALI Part 2a; dose confirmation expected in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalInitiation of the ASPENOVA Phase 3, randomized, confirmatory trial planned in 1H 2026 SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-d</description>
</item>
<item>
<title>Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-reports-third-quarter-210500271</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-reports-third-quarter-210500271</guid>
<pubDate>Mon, 10 Nov 2025 21:05:00 GMT</pubDate>
<description>DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback $280.7 million cash, cash equivalents and marketable securities supports runway into late 2027 SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class</description>
</item>
<item>
<title>Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-announces-inducement-grants-222500412</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-announces-inducement-grants-222500412</guid>
<pubDate>Mon, 03 Nov 2025 22:25:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on November 3, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 17,000 shares of the Company’s common stock to one (1) newly hired employee. The stock o</description>
</item>
<item>
<title>Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-participate-upcoming-investor-131500874</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-participate-upcoming-investor-131500874</guid>
<pubDate>Mon, 03 Nov 2025 13:15:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences: Guggenheim's 2nd Annual Healthcare Innovation Conference, Boston, MA. Fireside discussion, November 11, 2025, 3:30 p.m. ET. Stifel 2025</description>
</item>
<item>
<title>Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-announces-four-azenosertib-200500990</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-announces-four-azenosertib-200500990</guid>
<pubDate>Mon, 13 Oct 2025 20:05:00 GMT</pubDate>
<description>Presentations feature data from first-in-human Phase 1 study including Cyclin E1 biomarker findings, supporting late-stage development of azenosertibSAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that four azenosertib abstracts have been accepted for poster presentation at the AACR-N</description>
</item>
<item>
<title>Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-appoints-james-b-200500470</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-appoints-james-b-200500470</guid>
<pubDate>Tue, 26 Aug 2025 20:05:00 GMT</pubDate>
<description>Seasoned life sciences legal executive brings extensive public company experience, including broad strategic and financial transaction expertiseSAN DIEGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced the appointment of James B. Bucher, JD, as Chief Legal Officer and Corporat</description>
</item>
<item>
<title>Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-reports-second-quarter-200500098</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-reports-second-quarter-200500098</guid>
<pubDate>Wed, 06 Aug 2025 20:05:00 GMT</pubDate>
<description>DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback $303.4 million cash, cash equivalents and marketable securities supports operational runway into late 2027 SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially fir</description>
</item>
<item>
<title>Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-announces-inducement-grant-210000902</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-announces-inducement-grant-210000902</guid>
<pubDate>Tue, 01 Jul 2025 21:00:00 GMT</pubDate>
<description>SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on July 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company’s common stock to one (1) newly hired employe</description>
</item>
<item>
<title>Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-reports-first-quarter-200500648</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-reports-first-quarter-200500648</guid>
<pubDate>Wed, 14 May 2025 20:05:00 GMT</pubDate>
<description>First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million cash, cash equivalents and marketable securities supports operational runway into late 2027 SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a pote</description>
</item>
<item>
<title>Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-announces-first-patient-120000488</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-announces-first-patient-120000488</guid>
<pubDate>Mon, 28 Apr 2025 12:00:00 GMT</pubDate>
<description>Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced tha</description>
</item>
<item>
<title>Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-announces-poster-presentation-200500857</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-announces-poster-presentation-200500857</guid>
<pubDate>Wed, 23 Apr 2025 20:05:00 GMT</pubDate>
<description>SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that an abstract has been accepted for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025 in Chicago, IL. The poster will include clinical d</description>
</item>
<item>
<title>Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-reports-full-2024-200500775</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-reports-full-2024-200500775</guid>
<pubDate>Wed, 26 Mar 2025 20:05:00 GMT</pubDate>
<description>Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team to support execution of highly focused strategy $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027 SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis®</description>
</item>
<item>
<title>Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-present-multiple-posters-204000521</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-present-multiple-posters-204000521</guid>
<pubDate>Tue, 25 Mar 2025 20:40:00 GMT</pubDate>
<description>One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC) Three additional posters highlighting the potential for broad therapeutic applications of azenosertib as both a single agent and combination therapy as shown in preclinical models SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutic</description>
</item>
<item>
<title>Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer</title>
<link>https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-presents-updated-clinical-152500846</link>
<guid isPermaLink="true">https://6ix.com/company/zentalis-pharmaceuticals-llc/news/zentalis-pharmaceuticals-presents-updated-clinical-152500846</guid>
<pubDate>Sat, 15 Mar 2025 15:25:00 GMT</pubDate>
<description>Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate an objective response rate (ORR) of ~35% in response-evaluable patients On track to initiate Part 2 of the ongoing DENALI clinical trial in 1H 2025, with registration-intent topline data anticipated by year end 2026 Company also presents preclinical combination data of azenosertib with microtubule</description>
</item>
</channel>
</rss>